Patents Represented by Attorney, Agent or Law Firm Mary E. Gormley
-
Patent number: 6040301Abstract: For the oral administration of the anti-depressant mirtazapine an aqueous solution or suspension is found which is preferably stabilized by methionine, is thickened, and which has a pH of from 2.5 to 3. By the formulation according to the invention, an undesirable local anesthetic effect of mirtazapine is avoided.Type: GrantFiled: April 1, 1999Date of Patent: March 21, 2000Assignee: Akzo Nobel, N.V.Inventors: Arnold Titus Philip Skrabanja, Robert Edward Tully
-
Patent number: 6034067Abstract: The invention relates to a compound having formula (I), wherein A, B, X, N, Z and Q are defined as described in the description. The compounds of the invention have anticoagulant activity and can be used in treating or preventing thrombin-related diseases.Type: GrantFiled: August 12, 1998Date of Patent: March 7, 2000Assignee: Akzo Nobel, N.V.Inventors: Peter Diederik Jan Grootenhuis, Adrianus Petrus Antonius de Man, Anton Egbert Peter Adang
-
Patent number: 6033844Abstract: The present invention is directed to the identification of the causative agent of Porcine Reproductive Respiratory Syndrome virus and vaccines derived therefrom. The present invention is also directed to viral antigens produced by tissue culture cells infected with this virus, and the use of such antigens in diagnostics.Type: GrantFiled: May 27, 1997Date of Patent: March 7, 2000Assignee: Akzo Nobel, N.V.Inventors: Nicolaas Visser, Volker Ohlinger
-
Patent number: 6019983Abstract: The present invention is concerned with vaccination of mammals against GnRH. The vaccine comprises a GnRH peptide conjugate to E. coli fimbrial-filaments and elicits an immune response against GnRH.Type: GrantFiled: August 29, 1995Date of Patent: February 1, 2000Assignee: Akzo Nobel N.V.Inventors: Anna Van Der Zee, Irma Marianne Van Die, Willem Pieter Martin Hoekstra, Josephus Theodorus Gielen
-
Patent number: 6013266Abstract: The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagonostic tests for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strain and vaccine strains.Type: GrantFiled: April 9, 1998Date of Patent: January 11, 2000Assignee: Akzo Nobel, N.V.Inventors: Ruud Philip Antoon Maria Segers, Joachim Frey
-
Patent number: 6011025Abstract: The invention relates to a 11-(substituted phenyl)-estra-4,9-diene derivative of formula I ##STR1## wherein A, X, R.sub.1 and R.sub.2 are as defined by the specification. The compounds of the invention have anti-glucocorticoid activity and can be used in treating or preventing glucocorticoid-dependent diseases.Type: GrantFiled: September 22, 1997Date of Patent: January 4, 2000Assignee: Akzo Nobel, N.V.Inventor: Ronald Gebhard
-
Patent number: 6008327Abstract: The present invention relates to peptides immunochemically reactive with antibodies to the Epstein-Barr virus (EBV), comprising at least part of the VCA-p18 or VCA-p40 protein, encoded within the EBV open reading frames BFRF3 and BdRF1 respectively, or a functional variant thereof. The invention further relates to nucleic acid sequences encoding these peptides, monoclonal antibodies against these peptides, cell lines capable of producing monoclonal antibodies and anti-idiotype antibodies. The invention also relates to recombinant vector molecules comprising a nucleic acid sequence according to the invention and host cells transformed or transfected with these vector molecules. The invention is further concerned with immunological reagents and methods for the detection of EBV or anti-EBV antibodies and a method for the amplification and detection of Epstein Barr viral nucleic acid.Type: GrantFiled: April 3, 1995Date of Patent: December 28, 1999Assignee: Akzo Nobel, N.V.Inventors: Jaap M. Middeldorp, Wouterus M. J. van Grunsven
-
Patent number: 6005124Abstract: The invention relates to a method for the preparation of a steroid derivative ketal of formula I: ##STR1## characterized in that a compound of formula II: ##STR2## is treated with an alcohol in the presence of an orthoester, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined by the specification.Type: GrantFiled: January 4, 1999Date of Patent: December 21, 1999Assignee: Akzo Nobel, N.V.Inventors: Franciscus Theodorus Leonardus Brands, Pieter Vrijhof
-
Patent number: 6001363Abstract: This invention relates to a novel Eimeria protein with immunogenic properties as well as to DNA sequences encoding these proteins. This protein can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding this protein can be used for the preparation of a vector vaccine against coccidiosis.Type: GrantFiled: January 26, 1998Date of Patent: December 14, 1999Assignee: Akzo Nobel, N.V.Inventors: Fiona Margaret Tomley, Paul Patric James Dunn, Janene Marylin Bumstead, Arnoldus Nicolaas Vermeulen
-
Patent number: 5998639Abstract: The invention relates to a method for the preparation of a mixture of sulfated estrogens containing delta(8,9)-dehydro estrone [delta(8,9)DHE] or derivatives thereof.Type: GrantFiled: May 7, 1997Date of Patent: December 7, 1999Assignee: Akzo Nobel, N.V.Inventors: Petrus Hendricus Raijmakers, Robert Gerrit Hofstraat, Henricus Petrus Antonius Johannes Maria van den Boom
-
Patent number: 5994080Abstract: Blood clot formation is the key event in myocardial infarction. Besides increased coagulation, failure in blood clot lysis can induce undesired coronary thrombosis. Plasmin is essential for degradation of fibrin clots. Tissue-type plasminogen activator (t-PA) is the serine protease that converts plasminogen into plasmin. The association of the Alu insertion/deletion polymorphism in intron h of the t-pA gene to the risk of myocardial infarction was evaluated. Subjects with a documented history of myocardial infarction (n=162) and controls (n=258) were drawn from the Rotterdam Study, a population-based cohort study of 7983 subjects of 55 years or older. Allele frequencies were 0.54 for the insertion allele (t-PA Alu-h I) and 0.46 for the deletion allele, and were in Hardy Weinberg equilibrium. Among subjects that were homozygous for the insertion (n=138) were more than twice as many subjects with myocardial infarction compared to those homozygous (n=75) for the deletion (relative risk of 2.04, (95% CI 1.03-4.Type: GrantFiled: February 20, 1998Date of Patent: November 30, 1999Assignee: Akzo Nobel, N.V.Inventors: Diederick Egberstus Grobbee, Cornelis Kluft
-
Patent number: 5977099Abstract: The invention relates to a pharmaceutical composition comprising mirtazapine, a selective serotonin reuptake inhibitor (SSRI) and pharmaceutically acceptable auxiliaries. In particular the SSRI is selected from fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, sertraline, paroxetine, ifoxetine, cyanodothiepin and litoxetine. The composition which can be used to treat depressant patients has less side effects than treatment of the patients with mirtazapine or the SSRI alone.Type: GrantFiled: June 16, 1997Date of Patent: November 2, 1999Assignee: Akzo Nobel, N.V.Inventor: Victor Johannes Nickolson
-
Patent number: 5965353Abstract: The invention relates to a peptide or fragment thereof which is immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. A new monoclonal antibody directed to said peptide or fragment thereof is also part of the invention. The invention also relates to a method for the detection of EBV or anti-EBV antibodies in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the said detection methods. Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal; directed to the said peptide, which have the characteristics of detecting both native and denatured intact, functional EBNA-1 protein is also part of said invention.Type: GrantFiled: May 11, 1994Date of Patent: October 12, 1999Assignee: Akzo Nobel N.V.Inventor: Jaap Michiel Middeldorp
-
Patent number: 5965106Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.Type: GrantFiled: June 5, 1995Date of Patent: October 12, 1999Assignee: PerImmune Holdings, Inc.Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm Vogel
-
Patent number: 5965134Abstract: This application is concerned with immunogenic polypeptides of pestiviruses, specifically Classical Swine Fever Virus (CVFV), specifically the nonstructural protein p10, more specifically T-cell epitopes from this protein and nucleic acid molecules encoding these polypeptides, and vaccines and diagnostics with these polypeptides or nucleic acid molecules.Type: GrantFiled: September 24, 1997Date of Patent: October 12, 1999Assignee: Akzo Nobel, N.V.Inventors: Heinz-Jurgen Thiel, Knut Elbers, Thomas Pauly
-
Patent number: 5955622Abstract: The invention relates to a method for the preparation of a compound of formula II: ##STR1## wherein a compound of formula V: ##STR2## is condensed with a compound of the formula CH.sub.3 -C(OR.sub.4 O)-(CH.sub.2).sub.3 -XHal and R.sub.1, R.sub.2, R.sub.3, R.sub.4, X and Hal are as defined by the specification.Type: GrantFiled: August 5, 1998Date of Patent: September 21, 1999Assignee: Akzo Nobel, N.V.Inventors: Franciscus Theodorus Leonardus Brands, Pieter Vrijhof
-
Patent number: 5939073Abstract: There is described a novel virus which is the causative agent of fish pancreatic disease, which is a serious disease affecting Atlantic salmon. A method of isolating the virus through co-cultivation of infected tissues following by passage is described and an isolated strain of the virus has been deposited. The use of the virus, or proteins or polypeptide derived therefrom as a vaccine or in diagnosis is described, together with genetically engineered constructs.Type: GrantFiled: October 18, 1995Date of Patent: August 17, 1999Assignee: Akzo Nobel N.V.Inventors: Marian F. McLoughlin, Robert Thomas Nelson
-
Patent number: 5935582Abstract: The present invention is concerned with a hog cholera virus vaccine comprising a polypeptide characteristic of hog cholera virus. Vector vaccines capable to express a nucleic acid sequence encoding such a polypeptide also from part of the present invention. Said polypeptide and nucleic acid sequence can also be used for the detection of hog cholera virus infection.Type: GrantFiled: April 14, 1998Date of Patent: August 10, 1999Assignee: Akzo Nobel, N.V.Inventors: Gregor Meyers, Tillmann Rumenapf, Heinz-Jurgen Thiel
-
Patent number: 5929028Abstract: The invention concerns a liquid gonadotropin-containing formulation characterised in that the formulation comprises a gonadotropin and stabilising amounts of a polycarboxylic acid or a salt thereof and of a thioether compound. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with the particular stabilizers in an aqueous solution. The preparations contain a sufficient amount of the polycarboxylic acid or a salt thereof, preferably sodium citrate, and a sufficient amount of the thioether compound, preferably methionine, to stabilize the protein. The preparations preferably also include a nonreducing disaccharide like sucrose, and a non-ionic surfactant.Type: GrantFiled: April 14, 1998Date of Patent: July 27, 1999Assignee: Akzo Nobel, N.V.Inventors: Arnold Titus Philip Skrabanja, Petrus Johannes Maria van den Oetelaar
-
Patent number: H1825Abstract: An isothermal transcription based amplification assay for the detection of HTLV I RNA uses primers and probes for sequences within the tax gene, the pol gene, or the gag gene. An isothermal transcription based amplification assay for the detection of HTLV II uses primers and probes for sequences within the tax gene. Target specific primers and probes are also disclosed.Type: GrantFiled: January 30, 1998Date of Patent: December 7, 1999Assignee: Akzo Nobel N.V.Inventors: Joseph W. Romano, Roxanne Shurtliff, Kimberly G. Williams